Endocrine alterations are frequently found in patients undergoing treatment for CNS tumors. Careful follow-up aimed at the early detection of recurrences, with life-long monitor of hypothalamus-pituitary (HP) function, will also reveal any endocrine dysfunctions; indeed, their appropriate diagnosis and treatment may determine a significant improvement in the quality of life of these patients. The frequency of endocrine sequelae depends on (1) tumor site, (2) patient age at treatment initiation, and (3) type of therapy administered (surgery, radiotherapy, chemotherapy, steroids).
Endocrine Dysfunction in Patients Treated for Brain Tumors: Incidence and Guidelines for Management
LUMACHI, FRANCO;
2000
Abstract
Endocrine alterations are frequently found in patients undergoing treatment for CNS tumors. Careful follow-up aimed at the early detection of recurrences, with life-long monitor of hypothalamus-pituitary (HP) function, will also reveal any endocrine dysfunctions; indeed, their appropriate diagnosis and treatment may determine a significant improvement in the quality of life of these patients. The frequency of endocrine sequelae depends on (1) tumor site, (2) patient age at treatment initiation, and (3) type of therapy administered (surgery, radiotherapy, chemotherapy, steroids).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
